# Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

> **NCT05677334** · PHASE4 · COMPLETED · sponsor: **First Affiliated Hospital of Guangxi Medical University** · enrollment: 210 (actual)

## Conditions studied

- Type2diabetes

## Interventions

- **DRUG:** Henagliflozin
- **DEVICE:** Continuous Subcutaneous Insulin Infusion

## Key facts

- **NCT ID:** NCT05677334
- **Lead sponsor:** First Affiliated Hospital of Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05677334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05677334, "Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05677334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*